<DOC>
	<DOCNO>NCT00687817</DOCNO>
	<brief_summary>The primary objective study determine overall response rate ( complete response + partial response ) combination bavituximab plus carboplatin paclitaxel patient previously untreated locally advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Study Bavituximab Plus Paclitaxel Carboplatin Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Adults age 18 year age life expectancy least 3 month Histologically cytologically confirm nonsmall cell lung cancer stage IIIB ( pleural effusion ) , stage IV , recurrence Measurable disease cross sectional imaging least 2 cm long diameter ( 1 cm measure spiral CT ) Adequate hematologic ( ANC ≥ 1500 cells/µL ; Hemoglobin ≥9 g/dL ; platelet ≥100,000/µL ≤500,000/µL ) , renal ( serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 60 mL/min ) , hepatic function ( bilirubin ≤ 1.5 x ULN , ALT ≤ 3 x ULN , AST ≤ 3 x ULN ) Ddimer ≤ 2 x ULN Key Small cell mixed histology Known history bleed diathesis coagulopathy Any current evidence clinically significant bleeding define gross hematuria , hemoptysis , GI bleed Any history thromboembolic event ( e.g. , deep vein thrombosis pulmonary thromboembolism ) Prior chemotherapy , immunotherapy radiotherapy area measurable disease unless disease recur radiotherapy Radiotherapy within 2 week precede Study Day 1 Symptomatic clinically active CNS disease metastatic lesion Major surgery within 4 week Study Day 1 Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease ) Any history angina pectoris , coronary artery disease cerebrovascular accident , transient ischemic attack A history condition require antiplatelet therapy exception general cardiovascular prophylaxis aspirin . Antiplatelet agent prohibit study . Requirement chronic daily treatment NSAIDs , antiplatelet drug , steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>NSCLC</keyword>
</DOC>